Antithyroid drugs, which have been available for more than half a century, are important in
the management of hyperthyroidism, particularly in patients with Graves' disease, who have …

Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

Graves' disease (GD) is a systemic autoimmune disorder characterized by the infiltration of
thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R) …

Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies.
Appropriate treatment requires an accurate diagnosis and is influenced by coexisting …

Thyroid nodules are detected in up to 50 to 60% of healthy subjects. Most nodules do not
cause clinically significant symptoms, and as a result, the main challenge in their …

Abstract American Association of Clinical Endocrinologists, Associazione Medici
Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for …

The purpose of the present guidelines on the 131 I therapy of benign thyroid disorders
formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is …

This document provides the new EANM guideline on radioiodine therapy of benign thyroid
disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners …

AACE= American Association of Clinical Endocrinologists; AFTN= autonomously functioning
thyroid nodule; AME= Associazione Medici Endocrinologi; BEL= best evidence level; CNB …

OBJECTIVE: To review the etiology, diagnosis, and clinical presentation of Graves disease
and provide an overview of the standard and adjunctive treatments. Specifically, antithyroid …